Reuters logo
BRIEF-Urogen Pharma sees U.S. IPO priced between $12-$14/shr
April 24, 2017 / 10:49 AM / 8 months ago

BRIEF-Urogen Pharma sees U.S. IPO priced between $12-$14/shr

April 24 (Reuters) - Urogen Pharma Ltd:

* sees U.S. IPO of 3.46 million ordinary shares to be priced between $12.00 and $14.00 per share - SEC filing

* Urogen Pharma Ltd- expects to use about $17 million of IPO net proceeds to complete single pivotal Phase 3 trial of mitogel for treatment of low-grade UTUC

* Urogen Pharma Ltd- expects to use about $14 million of IPO net proceeds to file IND for, and to initiate phase 2b clinical trial of, Vesigel Source text: (bit.ly/2pVVSn4)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below